Participants 20 123 6
adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma
Participants 189 291 5
tumor-infiltrating lymphocytes (TIL) as adjuvant therapy for stage III (regional lymph nodes) melanoma
Participants 293 362 7
After lymph node excision, patients without any detectable metastases
Participants 547 632 9
Eighty-eight patients determined as eligible for treatment were enrolled in the study
Participants 924 962 3
group with only one invaded lymph node
Participants 1278 1368 3
the group with more than one invaded lymph node whatever the number of invaded lymph nodes
Participants 1764 1820 3
future vaccine development for the treatment of melanoma
